It is believed that metastasis through the cardiovascular system is primarily caused by circulating tumor cells (CTCs). We report an approach to eliminate circulating tumor cells from the blood stream by flowing the blood though an extracorporeal tube and applying photodynamic therapy (PDT). Chlorin e6 (Ce6), a photosensizer, was conjugated to antibody CD44 in order to target PC-3, a prostate cancer cell line. PC-3 cells were successfully stained by the Ce6-CD44 antibody conjugate. PDT was performed on whole blood spiked with stained PC-3 cells. As the blood circulated through a transparent medical tube, it was exposed to light of a specific wavelength generated by an LED array. A 2 minute exposure was sufficient to achieve selective cancer cell necrosis. Control studies showed no cell death.
Introduction
Cancer metastasis is a major culprit for cancer death, given that it is responsible for over 90% of overall cancer deaths [1] . Metastasis occurs through the lymphatic or the cardiovascular system. In metastasis through the cardiovascular system, some primary cancer cells shed to the blood stream, circulate, and ultimately colonize other organs. Thus, circulating tumor cells (CTC) have a key role in cancer metastasis. A number of researchers have focused on detecting, enriching, and enumerating CTCs employing a number of mechanisms including: micro-fluidic separation devices [2] [3] [4] , devices that rely on size exclusion by centrifugation [5, 6] or filtration [7, 8] , immuno-magnetic separation [9, 10] , and fluorescence activated cell sorting (FACS) technologies [2, 11] and several more techniques or combinations thereof. These technologies aim at diagnosis and are constrained by the small blood sample volume.
We hypothesize that removal of CTCs from the blood stream may reduce the chance of metastasis and the aggressiveness of existing tumors [12] . Recent studies report that there is indirect evidence that blood filtering, such as hemodialysis, might reduce cancer metastasis and the probability of cancer death by removing circulating tumor cells (CTCs) and other tumor growth factors from the bloodstream [13] [14] [15] . The rare frequency of CTCs and their presence in the circulatory system make traditional treatment modalities such as surgery, radiation, and chemo nearly impossible.
Extracorporeal filtration devices using leukocyte depletion filters have been used during tumor surgical procedures to remove tumor cells in order to reduce the risk of their dissemination [13] [14] [15] , however these devices were not used to reduce metastasis post surgery.
There have been efforts to remove or kill cancer cells using microtubes functionalized with antibodies, selectin, and cancer-specific tumor necrosis factor (TNF) -related apoptosis inducing ligand (TRAIL) with a capture and a kill rate between 30-41% [16, 17] . Recently a promising technique involved functionalizing circulating leukocytes with TRAIL and Eselectin adhesion receptor [18] . In a recent effort, our group functionalized a simple medical grade tube with EpCAM antibodies and successfully captured PC-3 cells in whole blood [19] .
We propose an approach using extracorporeal photodynamic therapy (PDT, photoimmunotherapy in conjunction with antibody targeting). PDT requires three components, namely: oxygen, a photosensitizer, and light (mainly at the visible range). All these have to be present at the same time for the photosensitizer to be activated, generate reactive oxygen (mainly singlet oxygen, 1 O 2 ), and damage cells or tissues. Furthermore, the toxicity of the reactive oxygen species is localized at the cell in direct contact with it due to its short (< 100 nm) diffusion distance [20, 21] . These characteristics result in high specificity to target with near zero collateral damage to adjacent cells/tissues and result in an effective and safer treatment compared to conventional radiation and chemotherapy. In spite of these advantages, near-visible light can barely penetrate through tissue [22, 23] , especially in the presence of blood (visible light absorber) and water (IR light absorber) and thus the application of PDT is mainly limited to diseases in opened/topical regions, including skin, head, neck, lung, teeth, etc.
We have developed a photosensitizer (Ce6) -antibody (anti-CD44) conjugate (Ce6-CD44 Ab conjugate) to selectively deliver the photosensitizing agent to CTCs (PC-3 cells in this case). An additional benefit to this technique is that the antibody can be safely cleared out of body by natural antibody degradation mechanisms within a few days [24] . PDT was performed by letting the blood flow through a thin transparent medical tube (Fig. 1) . In this article, we demonstrate the proof-of-principle of this approach. 
Materials and Methods

Conjugation of Ce6 to CD44 antibody
Chlorin E6 
Cell culture
The PC-3 cell lines were propagated in RPMI media supplemented with 10% fetal bovine serum (FBS) and 1 % penicillin-streptomycin (PS). Passaging was done by trypsinization. Cell culture media, trypsin EDTA, and buffers were purchased from Life Technologies.
Photodynamic therapy setup
PDT was performed using high power (maximum 100 W input) 660 nm LED array shown in Fig. 2. (a) (LEDwholesalers.com). Samples were placed within an aluminum foil covered styrofoam chamber shown in Fig. 2 (b) and Fig. 2 (c) and illuminated. The duration of illumination was studied to determine the optimal and minimum required time for PDT treatment. 
PDT on PC-3 cells in a tube
PC-3 cells were suspended using 0.25% trypsin EDTA. The number density of floating cells was estimated by hemocytometry. 300,000 cell / mL were used for the study. 20 µL of Ce6-CD44 Ab conjugates were added to 1 mL cell suspension and incubated for 1 hour. 
Results
PDT on PC-3 cells on a 12-well plate
PC-3 cells were grown confluent on the substrate of a 12-well plate. After 1 hour of incubation with the Ce6-CD44 Ab conjugate, positive staining was confirmed by monitoring the FITC label on the CD44 antibody ( Supplementary Fig. 1 ). The cells were stained with a cell viability indicator, Calcein AM. Illumination with the LED was performed in the presence of either 0.5 mL of whole blood or, in the case of the positive control, in 0.5 mL RPMI media. The results are summarized in Fig. 3 . In the positive control in RPMI media nearly all of the PC-3 cells were killed within the first 15 minutes (in the 15 minutes we are including the 2 minutes of illumination) without any noticeable survival. This result demonstrates that the Ce6-CD44 Ab conjugate is a highly potent photosensitizer reagent with target specificity. In the presence of whole blood cell death was slowed down and a small population of cells survived after two hours. The most probable reason for these results is that hemoglobin in blood is blocking some of the light from reaching through to the cells at the bottom of the plate. Both negative controls showed negligible reduction in Calcein AM staining and thus there was no cell death observed. 3 . Results of photodynamic therapy after 2 minutes illumination on a plate. Cancer cells are stained with calcein AM. The left hand side "PDT in blood" column shows a slowdown in cell death compared to the "no blood" column because light is absorbed by blood. The negative controls do not exhibit cell death.
PDT on PC-3 cells in a tube
PC-3 cells spiked in whole blood were inserted in a thin laboratory tube to evaluate the efficacy of extracorporeal therapy. About 50,000 PC-3 cells pre-stained with Ce6-CD44 Ab conjugates and Calcein AM were spiked in 100 µL of whole blood. The cell killing effect was studied by monitoring the Calcein AM fluorescence in the presence of blood and also quantified by performing fluorescence imaging on a hemocytometer. The sample that contained the Ce6-CD44 Ab conjugate, and was illuminated, demonstrated successful celldeath. The samples showed similar initial density of fluorescing PC-3 cells prior to illumination (Fig. 4) . We monitored cell death after 60 min and 120 min and the results showed significant reduction in fluorescing cells for the cells that were treated with the Ce6-CD44 Ab conjugate and illuminated (Fig. 5) . The two negative controls (one with conjugate but without illumination, and the other without conjugate but with illumination) did not exhibited noticeable change in the density of fluorescing cells within the 2 hour of observation (Fig. 5) . PDT in a tube appears to be more effective in killing cells than in the 12-well plate. Fig. 4 . Results of photodynamic therapy in a tube with 2 min illumination. The tube's diameter is 1.02 mm, which is within the penetration depth of light given that the tube is illuminated from all directions, for this reason there is faster cell death compared to the results in media, as shown in the left hand side "PDT in blood" column. 
Discussion
PDT is an effective alternative treatment modality which addresses several of the drawbacks of conventional treatments in cancer and in other diseases. However, the absorption of visible light by blood (especially due to the red blood cells' hemoglobins) significantly reduces the penetration of light through tissue. This is evident in our results shown in "PDT in blood" column of Fig. 3 , where PC-3 cells were cultured on a 12-well plate.
Following a 2 minute illumination 2 hours later the some cells were still alive. In contrast, the cells in media were completely wiped out by the 2 minute illumination in the absence of blood within the first 15 minutes. This result clearly showed how much blood can hamper the PDT's efficacy.
The PDT results, from Fig. 4 , where a tube was used exhibited improved efficacy.
We believe that the improvement came from the utilization of the tube. The tube used in this study is a transparent PDMS (silicone) tube with 1.02 mm inner diameter. Since the light came from all the directions surrounding the tube in the reflective chamber, the thin diameter of tube allowed for nearly the entire sample to be within the penetration depth of light.
Allowing for more exposure to light resulted in better outcomes with PDT.
The experimental parameters used in this investigation, such as the choice of photosensitizer, the illumination time, the antibody, the type of tube material, size of tube (length and diameter), the light source etc. need fine tuning. These parameters should be further studied and optimized to obtain maximum efficacy of PDT, especially with consideration to in vivo constant flow conditions. A similar approach was suggested previously by Edelson et al. [26] where the "extracorporeal photopheresis (ECP)" concept was first reported. However, in this technology the blood is collected and separated by apheresis and buffy coat was treated with UV light and reinjected to the body. This technology is used to treat cutaneous T-cell lymphoma and graft-versus-host diseases (GVHD) in organ transplantation and is currently approved by the FDA. Our approach has the benefits of not requiring blood separation processing and of utilizing light in the far-red/near infrared wavelength that has deeper tissue penetration depth.
In addition, the photosensitizer-antibody conjugates can be used as an imaging contrast to detect metastasized cancers, allowing other treatment modalities, including endoscopic photodynamic therapy. What is more it would be interesting to examine the possibility of targeting the lymphatic system. Finally, this concept can be translated to target other diseases.
